Leqembi's EU review drags on; Sanofi gets a new development head
Today, a brief rundown of news involving Eisai, Biogen and Sanofi, as well as updates from Opthea, Novartis, and PTC Therapeutics.
The saga to get Eisai and Biogen's newer drug for Alzheimer's disease approved in Europe continues. On Tuesday, the partners disclosed that the European Commission, which makes the final call on what medicines are cleared for market in European Union, referred the Leqembi case to an 'appeal committee.' These committees offer representatives from member countries a forum to further discuss proposed actions, such as the approval of a drug marketing application. A key regulatory committee sided against Leqembi's approval last summer, but reversed course after Eisai appealed that decision. — Jacob Bell
Sanofi has made former GSK executive Chris Corsico its new head of development, according to an internal company communication obtained by BioPharma Dive. Corsico, whose new position is effective immediately, will report to Sanofi's global head of R&D Houman Ashrafian. At GSK, Corsico led development of the company's drug portfolio. He spent more than two decades at Boehringer Ingelheim previously. — Ned Pagliarulo
Eye drug maker Opthea has scrapped plans to develop a treatment for a form of age-related macular degeneration, and warned investors it could run out of funding. In a Monday announcement, the company said it would terminate its Phase 3 trial of sozinibercept, which was tested as a combination with Lucentis. There 'remains material uncertainty as to Opthea's ability to continue as a going concern,' said the company, which had $100 million in cash and equivalents as of the end of March. — Gwendolyn Wu
Novartis appointed Karen Hale as its new chief legal and compliance officer, the Swiss pharma said Sunday, replacing Klaus Moosmayer. Hale, who joined Novartis in 2021 from AbbVie to become its chief legal officer, will now also oversee the company's ethics and risk compliance policies. 'Strengthening enterprise-wide risk alignment and ensuring our commitment to ethics, compliance, and integrity remains a guiding force in everything we do,' Hale wrote in a LinkedIn post. — Gwendolyn Wu
After years of regulatory back-and-forth, the European Commission will not renew the marketing authorization of PTC Therapeutics' drug Translarna to treat Duchenne muscular dystrophy. Effectively, Translarna is no longer approved in Europe, although individual countries can use certain pathways to allow continued use. Translarna was initially authorized in Europe in 2014, but in 2022 failed a confirmatory testing. European regulators have repeatedly recommended against the drug's continued availability, but those decisions went through several appeals. PTC is still working to win approval of Translarna in the U.S., where it has been rejected multiple times, too. — Ned Pagliarulo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
A 'seismic' 39% tariff on Switzerland is rocking the watch world, and even pre-owned Rolexes could see price hikes
Watch collectors might want to skip the Rolex boutique and head straight for the pawn shop this year. That is, if the Trump administration's new 39% tariff on goods from Switzerland sticks. The White House released updated tariff plans on Thursday, raising the rate from the proposed 31% announced earlier this year. The tariff escalation caught the watch community off guard. Switzerland is a manufacturing hub for luxury watches like Rolex and Cartier. Eugene Tutunikov, CEO of watch marketplace Swiss Watch Expo, told Business Insider the announcement "was a complete shock" and that "its effects will be immediate." Leading brands, including Rolex, have already raised prices in the US this year, likely in response to tariffs, Morgan Stanley analysts wrote in a July report about the Swiss watch market. US imports of Swiss goods have faced a 10% baseline tariff since April. A new 39% tariff on Swiss imports to the US would put more pressure on luxury watchmakers. That could lead to higher prices on Swiss-made goods shipped to the US, or less inventory for American shoppers. While the Swiss government could still try to negotiate, the tariff is currently set to take effect on August 7. Collectors and watchmakers may soon have to reckon with this new reality. Joshua Ganjei, CEO of watch marketplace European Watch Company, thinks more shoppers will turn to pre-owned models of high-end watches like Rolexes over brand-new ones. After all, a secondhand watch from a US-based seller won't face the added cost of a new Swiss-made model shipped from overseas. "For many American collectors, the 39% tariff instantly turned new releases from Swiss brands into a luxury few can justify," Ganjei said. According to the Morgan Stanley report, pre-owned watch dealers have reported an increase in demand this year since Swiss-made brands began raising their prices in the US. Prices in the secondhand market have been falling since mid-2022, though the rate of decline has narrowed. Pre-owned watches could also get more expensive, though. While the inventory already in the US won't face tariffs, heightened demand could drive up prices on the secondary market as well. Tutunikov said he thinks the pre-owned market will react to higher tariffs "much faster" than large retailers and hike prices sooner. He expects prices on the secondary market to jump as much as 10% in the next month and potentially reach up to 35% in the next six months, "as demand overwhelmingly shifts to available inventory." "This isn't just a tax; it's a seismic event that will cause a stark divergence between the new and pre-owned markets," Tutunikov said.
Business Insider
a day ago
- Business Insider
Analysts Are Neutral on Top Healthcare Stocks: Bausch Health Companies (BHC), Sanofi (SNYNF)
Analysts fell to the sidelines weighing in on Bausch Health Companies (BHC – Research Report) and Sanofi (SNYNF – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bausch Health Companies (BHC) TD Cowen analyst Michael Nedelcovych maintained a Hold rating on Bausch Health Companies yesterday and set a price target of $7.00. The company's shares closed last Friday at $5.71. According to Nedelcovych has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.8% and a 27.9% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Takeda Pharmaceutical Company, Molecular Partners AG, and Coherus Biosciences. Currently, the analyst consensus on Bausch Health Companies is a Hold with an average price target of $8.33, implying a 44.1% upside from current levels. In a report issued on July 25, Truist Financial also maintained a Hold rating on the stock with a $6.78 price target. Sanofi (SNYNF) Kepler Capital analyst Nicolas Pauillac maintained a Hold rating on Sanofi on July 31 and set a price target of EUR95.00. The company's shares closed last Friday at $92.56, close to its 52-week low of $88.90. According to Pauillac is ranked #974 out of 9914 analysts. Currently, the analyst consensus on Sanofi is a Moderate Buy with an average price target of $127.69, implying a 38.0% upside from current levels. In a report issued on July 17, Deutsche Bank also maintained a Hold rating on the stock with a EUR100.00 price target.
Axios
2 days ago
- Axios
Tariffs are coming for your breakfast — but not your OJ
New tariffs are poised to make your breakfast a bit pricier, especially your morning cup of coffee — but your orange juice caught a break. Why it matters: Your morning staples are caught in the crossfire of global trade politics. The new tariff rates — the highest in nearly a century — will cost the average family about $2,400 this year, according to the Yale Budget Lab's latest analysis. The big picture: American consumers have been navigating sticky inflation for food prices, and breakfast costs have been a sore point. Coffee prices have been volatile due to crop issues in Brazil, while chocolate has soared on cocoa shortages. A new wave of tariff hikes targeting certain European and Latin American imports is expected to push prices higher. Coffee and chocolate prices By the numbers: Brazilian coffee will face a 50% tariff, up from 10%. Even a modest 10% tariff on Brazilian coffee could raise U.S. retail prices 6–8% within 90 days, Francisco Martin-Rayo, CEO and co-founder of Helios AI, tells Axios. Swiss chocolate and coffee are being hit with a 39% tariff, up from the 31% tariff on Switzerland exports announced in April. This could affect Nespresso, as parent company Nestlé says every capsule sold in the world is produced in one of three factories in Switzerland. Rising tariffs to hit fruit and vegetable prices Zoom in: Martin-Rayo said his firm is tracking price shocks across the produce aisle — from tomatoes and mangoes to avocados — where tariffs compound climate disruptions. The biggest consumer price impacts are expected to hit fresh fruits, including bananas and vegetables, as well as processed imports like canned tomatoes, he said. "In some cases, we're projecting 10–15% retail price hikes within a single quarter," he said. Why orange juice got an exemption The intrigue: Orange juice from Brazil was exempted from tariffs, even though oranges are grown in Florida and California. Chris Brigati, chief investment officer at San Antonio-based investment firm SWBC, told Axios the reason for the exemption "remains unclear," especially given Brazil's coffee was hit with a 50% tariff. "Perhaps Trump wanted to limit the potential pain to higher prices from tariffs, as supply shock impacts are likely to occur," Brigati said. Zoom out: U.S. production has plunged to the lowest level in 88 years due to " unfavorable weather and continuing disease problems," USDA data shows, noting citrus greening has been battering Florida crops. Imports now account for 90% of the U.S. orange juice supply — with half coming from Brazil, which dominates global production under brands like Tropicana, Minute Maid and Simply Orange.
